{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/epilepsy/prescribing-information/adverse-effects-of-antiepileptic-drugs/","result":{"pageContext":{"chapter":{"id":"0a33c3f0-2ae8-515f-a2ce-2deeae71dba9","slug":"adverse-effects-of-antiepileptic-drugs","fullItemName":"Adverse effects of antiepileptic drugs","depth":2,"htmlHeader":"<!-- begin field 8cae261b-0884-486f-8bf5-01b01032c650 --><h2>Adverse effects of antiepileptic drugs</h2><!-- end field 8cae261b-0884-486f-8bf5-01b01032c650 -->","summary":"","htmlStringContent":"<!-- begin item f3a801eb-66df-4345-8239-99c84a5be67f --><!-- begin field 803112f7-fdf9-423d-9b3f-82501e7741b6 --><ul><li><strong>Exacerbation of seizures </strong>— rarely antiepileptic drugs may exacerbate seizure frequency and/or severity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">ABPI, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">NICE, 2020</a>].<ul><li>This may occur within 1 month of starting treatment, or dose increases, and is reversible upon discontinuation or dose decrease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">ABPI, 2020</a>]. </li></ul></li><li><strong>Adverse effects of antiepileptic drugs are common and mostly mild, </strong>and in many cases dose-related and unpredictable, but a minority can be life threatening. Older people are more likely to experience adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">Thijs et al, 2019</a>]. <ul><li>The safety profile of valproate in paediatrics is comparable to adults, but some adverse effects are more severe or principally observed in children. There is a particular risk of severe liver damage, pancreatitis, and psychiatric disorders such as aggression, agitation, and disturbance in attention [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">ABPI, 2021</a>].</li><li>Many common adverse effects of antiepileptic drugs are linked to the speed of dose escalation and absolute quantities of medication given, rather than a specific mechanism of action [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">Krishnamurthy, 2016</a>]. <strong> </strong></li></ul></li><li><strong>Explain to the person common potential adverse effects</strong> and advise they seek urgent medical advice if they develop symptoms such as rash, bruising, or somnolence with vomiting, particularly if they have recently started treatment within the last few weeks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. <ul><li>Potentially serious idiosyncratic drug reactions usually occur during the first few weeks of treatment, such as rash (which is usually mild), but severe cutaneous reactions can affect up to 1 in 1000 people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].</li></ul></li><li><strong>Adverse effects will depend on the individual drug, but include:</strong><ul><li>Sedation and dizziness — common when starting antiepileptic drug therapy but usually resolve with time. Sedation may be less with newer antiepileptic drugs, for example lamotrigine, oxcarbazepine and levetiracetam [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li><li>Suicidal thoughts and behaviour — this applies to all antiepileptic drugs and may be seen as early as one week after starting treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">Krishnamurthy, 2016</a>]. Advise the person to report mood changes, or distressing or suicidal thoughts [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">Joint Formulary Committee, 2019</a>]. Monitor for any signs of neuropsychiatric issues that may be secondary to drug treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">NICE, 2014</a>]. </li><li>Acute psychotic reactions — seen occasionally with vigabatrin, topiramate and tiagabine, particularly if there is a previous history of psychiatric disease. Recovery usually occurs on withdrawal from the drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li><li>Weight gain or loss — associated with some antiepileptic drugs; consider this when discussing treatment with the person [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li><li>Skin rashes — rashes can occur in up to 10% of people taking carbamazepine, phenytoin, or lamotrigine. Most rashes are mild and resolve on discontinuation of the drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].<ul><li>Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in people taking lamotrigine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">ABPI, 2018</a>]. </li><li>Antiepileptic drug hypersensitivity syndrome (fever, rash, lymphadenopathy and multiorgan failure) is potentially life-threatening. It occurs within 8 weeks of exposure to a drug, and affects in about 5 in 10,000 people, mainly those taking carbamazepine, lamotrigine, or phenytoin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. The drug should be immediately withdrawn and specialist advice sought [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">Joint Formulary Committee, 2019</a>]. </li></ul></li><li>Impaired bone health — associated with chronic epilepsy and its treatment. People taking antiepileptic drugs should be given dietary and other lifestyle advice to minimise the risk of osteoporosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li><li>Minor blood dyscrasias — associated with many antiepileptic drugs; most need no action (for example mild leucopenia with carbamazepine, thrombocytopenia with sodium valproate). Severe blood dyscrasia occurs in 6 in 10,000 patients [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>].  </li><li>Elevation of liver enzymes — (gamma-glutamyl transferase 90%, alkaline phosphatase 30%) may be noted in people taking enzyme-inducing antiepileptic drugs. This is usually of no clinical significance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epilepsy/references/\">SIGN, 2018</a>]. </li></ul></li><li>For further information on the adverse effects of individual antiepileptic drugs, see the <a href=\"http://www.medicines.org.uk/emc\" data-hyperlink-id=\"227c7d33-e3cf-44bc-911d-a8f70156a458\">electronic Medicines Compendium</a> (eMC), or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"98de873a-6a86-4c64-acca-a8f70156a4c9\">British National Formulary</a> (BNF).</li></ul><!-- end field 803112f7-fdf9-423d-9b3f-82501e7741b6 --><!-- end item f3a801eb-66df-4345-8239-99c84a5be67f -->","topic":{"id":"f8129267-de9a-585d-9e33-8725cd832f5f","topicId":"b393b08f-0928-43ec-abde-ec6b4844fdee","topicName":"Epilepsy","slug":"epilepsy","lastRevised":"Last revised in January 2021","chapters":[{"id":"5b049e7f-5e24-5bcc-af53-ff98c396ad9e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6b88498d-4758-510e-afc3-ed87d1957cad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e31fe7a4-1ae2-5cd9-b804-0d4c44e53ebc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7a679807-bda2-5ee7-9bde-7ecdc0762be8","slug":"changes","fullItemName":"Changes"},{"id":"7e16f4d4-24ca-5628-ba07-c486b95e90c5","slug":"update","fullItemName":"Update"}]},{"id":"535dff27-4aaa-57fa-80a1-d274bd3b4e59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"48265493-8622-58e8-a018-48a3e42f1148","slug":"goals","fullItemName":"Goals"},{"id":"6c194eb8-ba43-5a68-a78f-51161a41e8db","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c76ab727-494d-527d-a154-b8c28b77d8a4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6d0101cf-ff01-5958-a6fb-ebfbd77e76fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d111772f-1391-5d7f-a517-24a28715a449","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"30ff44ac-b721-5577-a601-8c4d55fa848d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"59735dcb-eba6-5d18-bea9-06c5d9c7b253","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4966ce92-afe3-59eb-b304-caf674cc78ae","slug":"definition","fullItemName":"Definition"},{"id":"5bbc7943-77eb-54ab-a31a-50a8a32fb58b","slug":"causes","fullItemName":"Causes"},{"id":"2779c8f9-cdfd-5fc5-9a9e-ff78cc795095","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d76a05be-28cf-51f2-9112-94a3089622ef","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"397d1dd0-2884-5fe1-93ec-86f60bb3f9b0","slug":"complications","fullItemName":"Complications"},{"id":"22457087-3e91-5c25-b650-d494bac54036","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"58d6be4c-1ac7-5b65-b78e-bff25e6e76e6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9854a4d4-10b2-54cb-bde8-bd6851a2a8d3","slug":"assessment","fullItemName":"Assessment"},{"id":"e24eacf4-0b1d-5c8e-beb3-8e4373ee4f96","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0b45afa2-7eab-5f3c-baa9-bf2274759bb7","fullItemName":"Management","slug":"management","subChapters":[{"id":"ac1322eb-1276-5dd0-bc64-f83fe4b15961","slug":"suspected-epilepsy","fullItemName":"Scenario: Suspected epilepsy"},{"id":"e72ec2fc-c602-5ac7-9d71-792f49a18f1f","slug":"managing-an-epileptic-seizure","fullItemName":"Scenario: Managing an epileptic seizure"},{"id":"f0726760-8fbd-5900-8525-9c2c98180d5a","slug":"routine-epilepsy-review","fullItemName":"Scenario: Routine epilepsy review"},{"id":"c14abfdb-dd66-5da7-90f4-aed8bb06d929","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"dc732fc8-8397-5b8b-886e-654a3d37dedf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a9cc1abe-202c-5ec3-9fa2-4bc1e9003e29","slug":"prescribing-antiepileptic-drugs","fullItemName":"Prescribing antiepileptic drugs"},{"id":"0a33c3f0-2ae8-515f-a2ce-2deeae71dba9","slug":"adverse-effects-of-antiepileptic-drugs","fullItemName":"Adverse effects of antiepileptic drugs"},{"id":"3b7a2ba0-89af-5839-8597-3c9290c9dc23","slug":"enzyme-inducing-antiepileptic-drugs","fullItemName":"Enzyme-inducing antiepileptic drugs"}]},{"id":"b4c758e3-f2ef-5920-8a4b-057ce3f83d8e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"12d642de-145f-5602-a8e5-c6320aab1692","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0cb744d0-8999-57a7-87e5-e25e4df6722a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0ad13cb3-2b8b-56c4-824c-8f777375a7bf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17531a22-0a95-5a68-a007-18cb5384f001","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6b27fc25-7d42-5230-a79b-0c623eb6b606","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7dd141fa-9fe8-54b2-b10c-584815f12e6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4b23c7ea-9a6f-5491-aa41-741d7d52e107","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"dc732fc8-8397-5b8b-886e-654a3d37dedf","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}